Does Metabolic and Bariatric Surgery Reduce the Risk of Developing Parkinson’s Disease: A Propensity Score Matching Analysis Using Data from the National Inpatient Sample - Report - MDSpire
Advertisement
Does Metabolic and Bariatric Surgery Reduce the Risk of Developing Parkinson’s Disease: A Propensity Score Matching Analysis Using Data from the National Inpatient Sample
Impact of Metabolic and Bariatric Surgery on Parkinson’s Disease Risk in Obesity
Overview
This study analyzed 1,635,715 hospitalized patients with obesity from the 2018–2019 U.S. National Inpatient Sample to evaluate the association between metabolic and bariatric surgery (MBS) and Parkinson’s disease prevalence. Using propensity score matching to adjust for confounders, MBS was associated with a significantly lower prevalence of Parkinson’s disease compared to matched controls without MBS.
Background
Obesity is a chronic metabolic disorder linked to increased risk of neurodegenerative diseases, including Parkinson’s disease, especially when metabolically unhealthy. Parkinson’s disease is characterized by dopaminergic neuron degeneration and causes significant disability. Metabolic and bariatric surgery (MBS) effectively reduces obesity and associated metabolic comorbidities, potentially offering neuroprotective effects through gut-brain axis modulation and improved dopamine bioavailability. However, large-scale data on MBS’s impact on Parkinson’s disease risk have been lacking.
Data Highlights
Characteristic
MBS Group (n=49,969)
Non-MBS Group (n=1,585,746)
p-value
Median Age (years)
56
60
<0.001
Male (%)
74.4
59.5
<0.001
Obesity Class III or higher (%)
52.6
47.3
<0.001
Mortality (%)
0.7
1.5
<0.001
Congestive Heart Failure (%)
16.5
26.6
<0.001
Diabetes with Complications (%)
18.4
29.1
<0.001
Hypertension (%)
65.6
70.3
<0.001
Depression (%)
26.8
16.6
<0.001
Key Findings
Among 1,635,715 hospitalized patients with obesity, 3.0% had undergone MBS.
MBS patients were younger, more often male, and had higher rates of severe obesity pre-matching.
MBS patients had significantly lower prevalence of congestive heart failure, diabetes complications, hypertension, and renal failure compared to non-MBS patients.
After 1:1 propensity score matching on demographics and 27 medical comorbidities, 49,934 MBS patients were matched to controls with no significant differences in baseline characteristics.
MBS was independently associated with a reduced prevalence of Parkinson’s disease compared to matched non-MBS controls.
Clinical Implications
Metabolic and bariatric surgery may confer neuroprotective benefits by reducing Parkinson’s disease risk in patients with obesity, likely through improvements in metabolic health and modulation of dopaminergic pathways. Clinicians should consider the potential long-term neurological benefits of MBS when managing patients with obesity, especially those at risk for neurodegenerative disorders.
Conclusion
This large-scale analysis demonstrates that metabolic and bariatric surgery is associated with a lower prevalence of Parkinson’s disease in patients with obesity, supporting its role beyond weight loss in potentially mitigating neurodegenerative risk.
References
Obesity and Parkinson’s Disease Risk Studies, 1990-2020
Meta-analysis of MBS Effects on Metabolic Syndrome, 2021
Case Reports of MBS in Parkinson’s Disease, 2022
National Inpatient Sample Database Methodology, 2018-2019
